Understanding chemotherapy-induced intestinal mucositis and strategies to improve gut resilience-Reference-Cited by-同舟云学术

Understanding chemotherapy-induced intestinal mucositis and strategies to improve gut resilience

Published:2021-05-01 Issue:5 Volume:320 Page:G712-G719
ISSN:0193-1857
Container-title:American Journal of Physiology-Gastrointestinal and Liver Physiology
language:en
Short-container-title:American Journal of Physiology-Gastrointestinal and Liver Physiology

Author:

Sougiannis Alexander T.¹²,VanderVeen Brandon N.¹³,Davis J. Mark³⁴,Fan Daping³⁵,Murphy E. Angela¹³

Affiliation:

1. Department of Pathology, Microbiology and Immunology, School of Medicine, University of South Carolina, South Carolina

2. College of Medicine, Medical University of South Carolina, Charleston, South Carolina

3. AcePre, LLC, Columbia, South Carolina

4. Department of Exercise Science, Arnold School of Public Health, University of South Carolina, South Carolina

5. Department of Cell Biology and Anatomy, School of Medicine, University of South Carolina, South Carolina

Abstract

Intestinal mucositis, or damage to the intestinal mucosa, is a common side effect of chemotherapy. In this review, we describe the pathobiology of intestinal mucositis that is associated with chemotherapy treatments. In addition, we discuss the efficacy of several potential therapeutic strategies that have shown some potential in alleviating chemotherapies’ off-target effects.

Funder

HHS | NIH | National Center for Complementary and Integrative Health

Publisher

American Physiological Society

Subject

Physiology (medical),Gastroenterology,Hepatology,Physiology

Link

https://journals.physiology.org/doi/pdf/10.1152/ajpgi.00380.2020

Reference53 articles.

1. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics

2. Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapy

3. Mortality within 30 days of chemotherapy: a clinical governance benchmarking issue for oncology patients